John Randall, RPh
MOHS-Micrographic Surgery · West Lafayette, INNPI 1326076530
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.1% of the total across 436 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Novartis at 42.3% of the total.
Across 436 payments — averaging $13.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- AbbVie$1K
- Johnson & Johnson$768
- E.r. Squibb & Sons, L.L.C.$188
- Regeneron Healthcare Solutions, Inc.$181
- Genentech USA, Inc.$118
- plus $1K from 23 others
Across 453 payments — averaging $8792.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1.9M
- Incyte Corporation$993K
- Amgen$250K
- Taro Pharmaceuticals USA, Inc.$169K
- Bristol Myers Squibb$168K
- AbbVie$133K
- plus $329K from 8 others
What the payments were for
- Food & beverage$5,59794%
- Education$3486%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 217 | $2,516 |
| AbbVie(2 entities) | 89 | $1,145 |
| Johnson & Johnson | 50 | $768 |
| E.r. Squibb & Sons, L.L.C. | 11 | $188 |
| Regeneron Healthcare Solutions, Inc. | 8 | $181 |
| Genentech USA, Inc. | 6 | $118 |
| LEO Pharma Inc. | 6 | $116 |
| Galderma Laboratories, L.p. | 5 | $103 |
| Sanofi | 5 | $87 |
| Amgen | 5 | $85 |
| Pfizer | 5 | $72 |
| Lilly USA, LLC | 3 | $66 |
| UCB, Inc. | 3 | $58 |
| Sun Pharmaceutical Industries Inc. | 3 | $58 |
| Kerecis Limited | 2 | $46 |
| Biofrontera Inc. | 2 | $41 |
| Smith+Nephew | 2 | $37 |
| Bristol Myers Squibb | 2 | $34 |
| Organon | 1 | $30 |
| Mayne Pharma Commercial LLC | 1 | $29 |
| Merck | 2 | $27 |
| Integra Lifesciences Corporation | 1 | $24 |
| Verrica Pharmaceuticals Inc. | 1 | $20 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $19 |
| Dermavant Sciences, Inc. | 1 | $18 |
| Convatec Inc. | 1 | $17 |
| Incyte Corporation | 1 | $17 |
| VYNE Pharmaceuticals Inc. | 1 | $15 |
| Genentech, Inc. | 1 | $13 |
How this compares
Too few mohs-micrographic surgery providers in Indianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErivedgeVismodegib | 28 | $405,051 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 22 | $163,237 |
| OtezlaApremilast | 15 | $77,030 |
| SantylCollagenase Clostridium Hist. | 15 | $20,395 |
| Tavaborole | 15 | $6,181 |
| Ammonium Lactate | 142 | $2,587 |
| Clobetasol Propionate | 35 | $2,002 |
| Fluorouracil | 22 | $1,549 |
| Betamethasone Dipropionate | 26 | $1,216 |
| Metronidazole | 22 | $1,075 |
| Ketoconazole | 70 | $880 |
| Tretinoin | 15 | $863 |
| CiclopiroxCiclopirox Olamine | 78 | $788 |
| Halobetasol Propionate | 14 | $713 |
| Famciclovir | 11 | $651 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech USA, Inc.Erivedge | $118 | $405,05128 claims |
| AmgenOtezla | $85 | $77,03015 claims |
| Smith+NephewSantyl | $37 | $20,39515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few mohs-micrographic surgery providers in Indianaon file to place this against a meaningful peer group, so we don't.
Other mohs-micrographic surgery in West Lafayette
- Carl HankeIndianapolis$96K
- Rachel WardMuncie$9K
- Eduardo RiveraMadison$8K
- David SurprenantEvansville$5K
- Brian WilliamsGreenwood$5K
- Perry HooperCarmel$5K
- Shayna GordonPlainfield$4K
- Jane LimEvansville$4K
- Thomas McGovernFort Wayne$4K
- Sreya TalasilaPortage$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.